GlassScriptPhysician profile
Meaghan Moxley
NPI 1669869632
$3,853.18
in general payments reported to CMS, 2019-2025
37 companies · $747 in 2025
The $747 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.53 · 2022: $840 · 2023: $1,188 · 2024: $981 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859 · Education: $56.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.12 |
| Education | $56.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $767.76 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $441.84 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $332.17 | 2021-2025 | |
| Radius Health, INC. | $265.44 | 2022-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $223.75 | 2021-2025 | |
| Corcept Therapeutics | $203.05 | 2022-2024 | Korlym |
| Amgen INC. | $187.96 | 2022-2025 | Tepezza, Prolia, Evenity |
| Ibsa Pharma INC. | $140.29 | 2022-2025 | Tirosint, Licart, Tirosint |
| Medtronic, INC. | $137.82 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Cequr Corporation | $96.25 | 2023-2024 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $92.60 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $85.32 | 2023-2025 | Unithroid |
| Insulet Corporation | $84.94 | 2022-2025 | Omnipod |
| Antares Pharma, INC. | $65.96 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Horizon Therapeutics Plc | $55.86 | 2021-2023 | Tepezza |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Embecta Corp. | $55.68 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Astrazeneca Pharmaceuticals LP | $54.10 | 2022-2023 | Farxiga |
| Dexcom, INC. | $49.04 | 2023-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $46.42 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $39.87 | 2025 | |
| Abbott Laboratories | $37.02 | 2024 | Freestyle Libre 3 |
| Beta Bionics, INC. | $35.04 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Alexion Pharmaceuticals, INC. | $35.02 | 2023 | Strensiq |
| Zealand Pharma US, INC. | $30.09 | 2021 | |
| Lifescan, INC. | $29.48 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.47 | 2025 | Jardiance |
| Sequel Med Tech, LLC | $25.16 | 2025 | Twiist |
| Becton, Dickinson and Company | $24.47 | 2022 | |
| Mannkind Corporation | $24.27 | 2023 | Afrezza |
| Kyowa Kirin, INC. | $23.87 | 2023 | Crysvita |
| Xeris Pharmaceuticals, INC. | $23.56 | 2023 | Gvoke Hypopen |
| Ipsen Biopharmaceuticals, INC | $22.46 | 2022 | |
| Amarin Pharma, INC. | $21.93 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.66 | 2025 | |
| Glaxosmithkline, LLC. | $17.96 | 2025 | Arexvy, Shingrix |
| Recordati_rare_diseases_inc. | $15.62 | 2025 | Isturisa |
| Merck Sharp & Dohme LLC | $14.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Moxley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.